Abstract: Cell proliferation activity and correlation between the LI (labeling index) of BrdU (5-bromo-2'-deoxyuridine) and the expression of the Ki-67 antigen or PCNA (proliferating cell nuclear antigen) were evaluated by immunohistochemistry in 18 canine spontaneous neoplasms. Spearman's rank correlation coefficient and linear regression analysis revealed a significant correlation between the BrdU LI and Ki-67 LI, BrdU LI and PCNA LI, and BrdU LI and MI (mitotic index) in each case [r s = 0.917, P < 0.01 (BrdU LI vs. Ki-67 LI), r s = 0.736, P < 0.01 (BrdU LI vs. PCNA LI), r s = 0.748, P < 0.01 (BrdU LI vs. MI) by Spearman's rank correlation coefficient; and r = 0.918, P < 0.01 (BrdU LI vs. Ki-67 LI), r = 0.626, P < 0.01 (BrdU LI vs. PCNA LI), r = 0.763, P < 0.01 (BrdU LI vs. MI) by linear regression analysis]. Ki-67 LIs were more closely correlated with BrdU LIs than PCNA LIs or MIs, and the Ki-67 antigen is useful as an endogenous proliferation marker in canine neoplasms. (J Toxicol Pathol 2006; 19: 123-127) 
Introduction
A number of methods can be employed for the detection of proliferating cells in tissue sections 1 . BrdU (Bromodeoxyuridine), which is a halogenated derivative of thymidine, has been the gold standard for the in vivo labeling of DNA 2 . BrdU is incorporated into the nuclei during the DNA synthetic phase of cell cycles (S phase), and it can be immunohistochemically detected by using an anti-BrdU antibody 3 . Although BrdU is incorporated into S-phase cells, the BrdU labeling method has some disadvantages, namely, administration to living animals and its mutagenic potential 3 . Therefore, instead of BrdU labeling, detection of cell cycle-specific antigens have been used as proliferating markers in more recent studies. The Ki-67 protein is an approximately 300-kDa nuclear and nucleolar protein, which is tightly associated with somatic cell proliferation 4 , and it is expressed in the early G1, S, G2, and M phases of the cell cycle 5 . PCNA (proliferating cell nuclear antigen) is a cofactor of DNA-polymerase delta, and it is first detected in the mid-G1 phase of the cell cycle. It reaches a maximum in the S phase and declines in the G2 phase 6 . The Ki-67 protein and PCNA are masked by formalin fixation and paraffin embedding, and antigen-retrieval treatment is subsequently required to unmask them. Based on extensive human and veterinary studies, it is obvious that the index of Ki-67-or PCNA-positive cells correlates with their proliferating potential 7 . In veterinary medicine, however, few studies have reported on the correlation between endogenous proliferating markers and exogenous labeling methods such as BrdU labeling 8, 9 . In this study, we investigated the use of anti-Ki-67 protein and anti-PCNA antibodies as proliferation markers in paraffin-embedded canine neoplastic tissues and compared the results with those of the BrdU-labeling method.
Materials and Methods

Animals, tissues, and BrdU labeling
In this study, 18 canine neoplastic tissue samples, which were surgically excised at the Veterinary Teaching Hospital of Gifu University or at private animal hospitals, were used. The mean age of the tumor-bearing animals was 10.3 years (range 5-17 years and age was not known in three cases). None of the animals had received chemotherapeutic drugs prior to the surgical excision of the tumor. The details of the samples are provided in Table 1 .
The BrdU-labeling method was performed on animals whose owners provided informed consent to the aims and methods of the study 10 . BrdU was purchased from SigmaAldrich Co. (St. Louis, MO, USA), and 3.0-83.3 mg was dissolved in 25 µl of dimethyl sulfoxide (Nacalai Tesque, Kyoto, Japan); 975 µl of 0.9% NaCl solution was then added. The BrdU solution was sterilized using a 0.22 µm filter (Millex-GV, Millipore Co. Bedford, MA, USA). One hour prior to the excision of the tumor, BrdU solution at a dose of 1 ml/kg body weight was administered intravenously to the animals 10 . Consequently, BrdU solutions were administered at doses ranging from 3.0-83.3 mg/kg body weight (Table 1) .
Histopathology and immunohistochemistry
The samples were fixed in 10% formalin solutions and embedded in paraffin wax; serial sections (4 µm) were then cut and these were stained with hematoxylin and eosin (H & E) for histopathological diagnoses. Histopathological diagnoses were based on a previous report 11 .
Immunostaining of BrdU-incorporated cells was performed in accordance with the method described by Yanai et al 10 . In brief, serial sections were mounted on a glass slide treated with aminopropyltriethoxysilane (SigmaAldrich Co.). After dewaxing and rehydrating, the serial sections were rinsed in phosphate-buffered saline (PBS, pH 7.4). DNA was then denatured using 5N HCl at 37°C for 30 min, before being neutralized in Palitisch's boric acid-NaClborate buffer (pH 7.6) at 4°C for 15 min. The sections were subjected to protease digestion using 0.04% pepsin (Wako Pure Chemical Industries, Osaka, Japan) at 37°C for 30 min in 0.01 N HCl. After inactivation of the endogenous peroxidase by 0.3% hydrogen peroxide in methanol at room temperature (RT) and blocking of non-specific antibody binding (5% normal goat serum; Chemicon, Temecula, CA, USA), the sections were incubated with the primary antiBrdU monoclonal antibody (×50, Dako cytomation A/S, Glostrup, Denmark) overnight at 4°C. After rinsing three times with PBS for a total period of 1 h, the sections were incubated with biotinylated anti-mouse IgG goat polyclonal antibody (Dako cytomation) for 30 min at RT. Following this, the sections were rinsed three times with PBS for a total period of 30 min, and incubated with horseradish peroxidase-conjugated streptavidin (Dako cytomation) for 30 min at RT. The sections were again rinsed three times with PBS for a total period of 30 min. The labeled cells were visualized using diaminobenzidine. Finally, the sections were counterstained using Mayer's hematoxylin. As a negative control, the primary antibody was replaced with normal mouse serum.
For the detection of the Ki-67 antigen and PCNA, we used the anti-Ki-67 antigen clone, MIB-1 mouse monoclonal antibody (Dako cytomation), and the anti-PCNA clone, PC10 mouse monoclonal antibody (Dako cytomation), respectively. Briefly, after dewaxing and rehydrating, the serial slides were immersed in 0.05 M citrate buffer (pH 6.8) and autoclaved at 120°C for 15 min. Next, the slides were gently rinsed with PBS and treated with 0.3% hydrogen peroxidase in absolute methanol for 30 min at RT to quench endogenous peroxidase. The sections were then incubated with 5% normal goat serum (Chemicon) for 1 h, followed by incubation with anti-Ki-67 monoclonal antibody (×50) or anti-PCNA monoclonal antibody (×100) at 4°C overnight. The remaining procedures were the same as those employed for immunolabeling with BrdU.
Assessment of immunolabeling and statistical analysis
The number of BrdU-, Ki-67-, or PCNA-positive cells among a total of 1000 cells (from 10 high power [×400] fields) were counted to obtain the BrdU LI (BrdU labeling index), Ki-67 LI (Ki-67 labeling index), and PCNA LI (PCNA labeling index), respectively. In addition, the number of mitotic figures among a total of 1000 cells in the H & E sections were counted to obtain the MI (mitotic index). The correlation between the BrdU LI and Ki-67 LI, BrdU LI and PCNA LI, and BrdU LI and MI was analysed by linear regression analysis and Spearman's rank correlation coefficient.
Results
The nuclei of neoplastic cells revealed positive reactions for BrdU or Ki-67 immunohistochemistry. In some cases of PCNA immunostaining, the positive reaction was observed not only in the nucleus but also in the cytoplasm.
The BrdU LI, Ki-67 LI, PCNA LI, and MI obtained in each case are listed in Table 1 . In all cases, the BrdU LIs were lower than the Ki-67 LIs or PCNA LIs. With the exception of three cases, PCNA LIs were higher than the Ki- 67 LIs in the all the cases (Table 1 ). Spearman's rank correlation coefficient and linear regression analysis revealed that the BrdU LI and Ki-67 LI, BrdU LI and PCNA LI, and BrdU LI and MI in each case were significantly correlated [r s = 0.917, P < 0.01 (BrdU LI vs. Ki-67 LI), r s = 0.736, P < 0.01 (BrdU LI vs. PCNA LI), and r s = 0.748, P < 0.01 (BrdU LI vs. MI) with Spearman's rank correlation coefficient; r = 0.918, P < 0.01 (BrdU LI vs. Ki-67 LI), r = 0.626, P < 0.01 (BrdU LI vs. PCNA LI), and r = 0.763, P < 0.01 (BrdU LI vs. MI)] with linear regression analysis. The estimated regression equations of Ki-67 LI, PCNA LI and MI on BrdU LI were (Ki-67 LI)=1.28(BrdU LI)+5.31, (PCNA LI)=1.20(BrdU LI)+16.27 and (MI)=0.04(BrdU LI)-0.021, respectively (Fig. 2) . In mammary gland neoplasms, each LI of BrdU, Ki-67, PCNA and mitosis of mammary carcinoma (averages: 7.0, 11.7, 27.5 and 0.32%, respectively) tended to be higher than that of mammary adenoma (averages: 14.9, 25.5, 31.3 and 0.6%, respectively).
Discussion
Accurate evaluation of proliferating cells is necessary to investigate the malignancy of a neoplasm. Mitotic figures obtained in H & E sections reflect the growth fraction of the neoplasm to a lesser extent because they remain in a cell cycle for a short duration. In addition, occasionally, the mitotic figures cannot be distinguished from pyknotic or apoptotic cells. In contrast to the mitotic figures, immunostaining of proliferating markers facilitates the detection of proliferating cells. BrdU is one of the accurate proliferating markers 12 ; however, BrdU labeling is specific to only S-phase cells. In contrast, the Ki-67 antigen is expressed in cycling cells and not in resting cells; therefore, the growth fraction can be detected more precisely. In our results, the mean of the Ki-67 LI of all neoplasms was higher than that of BrdU LI; the correlation coefficient between Ki-67 LI and BrdU LI was 1.3, and the expression rate of Ki-67, reflected in the Ki-67 LI, closely correlated with BrdU LI (r = 0.956). According to other reports on human neoplasms, the correlation coefficient between Ki-67 LI and BrdU LI of lung cancer was 1.26 (r = 0.97) 13 , that of bladder cancer was 1.37 (r = 0.95) 14 , and the data obtained in our study of canine neoplasms is in keeping with these reports. On the other hand, the correlation between PCNA LI and BrdU LI (r = 0.723) was weaker than that between Ki-67 LI and BrdU LI. Since PCNA has a long half-life time, the remaining PCNA protein is detected in recent G0 cells 15 . Moreover, PCNA is involved in the DNA repair process 16 . The weaker correlation between PCNA LI and BrdU LI can be attributed to the existence of G0 cells that have residual detectable PCNA protein or DNA repair process. In the three cases that indicated lower PCNA LI than Ki-67 LI, the epitope of PCNA might have been inactivated by fixation, although the actual cause was unclear in this study.
In our previous study, we have reported that an osteosarcoma, which has a clinically-and histologicallydetectable malignancy, revealed a significantly higher BrdU LI and Ki-67 LI than those in a chondrosarcoma 9 . Moreover, in canine mastocytomas, the increase in the BrdU LI and Ki-67 LI was proportional to the histological grade 8 . In this study, although the number of benign neoplasms was limited, the BrdU LI and Ki-67 LI of malignant mammary neoplasms were approximately three times higher than those of benign mammary neoplasms. Therefore, the BrdU LI and Ki-67 LI are useful quantitative markers for evaluating malignancy.
In conclusion, the correlation of each of Ki-67 and PCNA with BrdU LIs, as the gold standard of proliferation markers, is different. The PCNA LI has a weaker correlation with the BrdU LI because non-specific PCNA in non-cycling cells can also be detected. On the contrary, the Ki-67 LIs closely correlated with BrdU LIs, and therefore, the Ki-67 antigen is a useful endogenous proliferation marker in canine neoplasms.
